Efficacy and safety of rhTPO and rhIL-11 in preventing chemotherapy-induced thrombocytopenia in patients with malignancy: a meta-analysis
10.3760/cma.j.cn115355-20240509-00232
- VernacularTitle:rhTPO和rhIL-11预防恶性肿瘤化疗相关性血小板减少症有效性与安全性的Meta分析
- Author:
Linghua MENG
1
;
Shucheng YE
1
Author Information
1. 济宁医学院附属医院肿瘤科，济宁 272029
- Publication Type:Journal Article
- Keywords:
Neoplasms;
Thrombocytopenia;
Recombinant human thrombopoietin;
Recombinant human interleukin-11;
Chemotherapy
- From:
Cancer Research and Clinic
2025;37(4):292-297
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To investigate the efficacy and safety of recombinant human thrombopoietin (rhTPO) and recombinant human interleukin-11 (rhIL-11) in preventing chemotherapy-induced thrombocytopenia (CIT) in malignant tumors.Methods:The literatures on rhTPO and rhIL-11 in preventing CIT in malignancies were retrieved from the PubMed, Embase, Cochrane Library, China National Knowledge Infrastructure (CNKI) and Wanfang database. The search period was from the establishment time of databank to December 2023. According to inclusion and exclusion criteria, literatures screening, data extraction, and the quality evaluation of the literatures were performed, and then the data was analyzed by using Review Manager 5.4 software. The lowest platelet count after chemotherapy, the duration of platelet count < 50×10 9/L after chemotherapy, the time for platelet count to recover to ≥ 75×10 9/L after chemotherapy, the time for platelet count to recover to ≥ 100×10 9/L after chemotherapy, platelet transfusions, and adverse reactions were compared between the rhTPO or rhIL-11 prophylactic group and the control group. Results:A total of 7 articles were included, containing 444 patients aged 14-73 years old. Meta analysis showed that prophylactic use of rhTPO or rhIL-11 could increase the minimum platelet count after chemotherapy [standardized mean (SMD) = 23.86, 95% CI: 19.50-28.21, P < 0.001], shorten the time for platelet count recovery to ≥ 75×10 9/L after chemotherapy (SMD= -7.47, 95% CI: -10.34--4.60, P < 0.001), shorten the time for platelet count recovery to ≥ 100×10 9/L after chemotherapy (SMD = -5.80, 95% CI: -10.01--1.59, P < 0.001), shorten the duration of platelet count < 50×10 9/L after chemotherapy (SMD = -0.74, 95% CI: -1.18--0.29, P = 0.001), and reduce platelet transfusion and adverse reactions. Conclusions:rhTPO and rhIL-11 have good efficacy and safety in preventing CIT of malignant tumors.
